ArticleAlimentary pharmacology & therapeutics2023

Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in patients with inflammatory bowel disease.

Nicolas Richard et al.PubMed ↗Publisher ↗

No numbers read from the abstract.